Alibaba
BABA
Micron Technology
MU
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
US Stock MarketDetailed Quotes
SWTX SpringWorks Therapeutics
- 57.430
- -1.160-1.98%
Close Feb 14 16:00 ET
- 59.900
- +2.470+4.30%
Pre 06:06 ET
4.27BMarket Cap-14.76P/E (TTM)
60.000High57.270Low2.78MVolume58.910Open58.590Pre Close162.75MTurnover4.03%Turnover RatioLossP/E (Static)74.39MShares60.00052wk High8.02P/B3.97BFloat Cap28.21052wk Low--Dividend TTM69.04MShs Float96.480Historical High--Div YieldTTM4.66%Amplitude13.600Historical Low58.520Avg Price1Lot Size
SpringWorks Therapeutics News
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $87
Evercore Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $65
Wedbush Adjusts Price Target on Springworks Therapeutics to $81 From $77, Maintains Outperform Rating
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $66
SpringWorks Therapeutics Is Maintained at Outperform by Evercore ISI Group
SpringWorks Therapeutics Price Target Raised to $65.00/Share From $60.00 by Evercore ISI Group
SpringWorks Therapeutics Analyst Ratings
H.C. Wainwright Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $74
Buy Rating for Springworks Therapeutics Boosted by FDA Approval of GOMEKLI and Strong Market Potential
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $66
Evercore Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $60
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Springworks Therapeutics (SWTX)
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $65
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
Evercore ISI Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $55
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $55 to $63
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.